News
![Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?: https://g.foolcdn.com/editorial/images/738452/investor-stands-in-kitchen-considering-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0aedf0460c35e4cdaced95c51ab3488c4ee294e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stands-in-kitchen-considering-laptop.jpg?locale=us)
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?
For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining
![Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?: https://g.foolcdn.com/editorial/images/738452/investor-stands-in-kitchen-considering-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzVEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0aedf0460c35e4cdaced95c51ab3488c4ee294e5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-stands-in-kitchen-considering-laptop.jpg?locale=us)
Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More?
For a generic drugmaker like Viatris (NASDAQ: VTRS), big spurts of growth are unlikely. The market for low-cost generic medications is competitive, and success is largely defined by maintaining
![These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2NwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--103827aa67bdf4171dd1e1b391816c7491f5b037/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=us)
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
![These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys: https://g.foolcdn.com/editorial/images/735027/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2NwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--103827aa67bdf4171dd1e1b391816c7491f5b037/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=us)
These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys
You can secure a 5% dividend yield without being too risky or aggressive. Sometimes, it's a matter of jumping on a good opportunity when it arises. A stock can fall in value for various reasons
![It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?: https://g.foolcdn.com/editorial/images/732730/three-investors-meet-with-paperwork.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODhSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--05bb944f2d886fae0c18acf9ef5620c14c4bbd9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/three-investors-meet-with-paperwork.jpg?locale=us)
It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If
![It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?: https://g.foolcdn.com/editorial/images/732730/three-investors-meet-with-paperwork.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODhSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--05bb944f2d886fae0c18acf9ef5620c14c4bbd9c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/three-investors-meet-with-paperwork.jpg?locale=us)
It's Cheap and Pays a Big Dividend, But Is Viatris Stock a Buy?
Companies that produce generic drugs aren't known for being exciting investments, and there's little chance they'll ever expand as fast as your average tech stock or most other growth stocks. If
![Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q1 2023 Earnings CallMay 03, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Why Shares of Adaptimmune Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/727860/dna-genetic-sequencing-biotech-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG5zYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--280ffaebd19399c2465b1009a297637f5dc516f9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dna-genetic-sequencing-biotech-1.jpg?locale=us)
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
Alacer Corp. today announced the launch of Natean®, a new eco-conscious oral healthcare brand providing products to consumers looking for nature-inspired toothpastes that deliver essential oral
![Astra Zeneca: Wirbel um COVID-19-Impfstoff](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Astra Zeneca: Wirbel um COVID-19-Impfstoff
AstraZeneca (WKN: 886455) teilte am Montag mit, dass die Nebenwirkungen seines potenziellen Corona-Impfstoffs bei älteren Menschen geringer seien. Die Wirkstoff-Hoffnung des britischen Pharmariesen
![Astra Zeneca: Wirbel um COVID-19-Impfstoff](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Astra Zeneca: Wirbel um COVID-19-Impfstoff
AstraZeneca (WKN: 886455) teilte am Montag mit, dass die Nebenwirkungen seines potenziellen Corona-Impfstoffs bei älteren Menschen geringer seien. Die Wirkstoff-Hoffnung des britischen Pharmariesen
![AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!
Rückschlag beim Corona-Impfstoff: Die britische Pharmaschmiede AstraZeneca (WKN: 886455) stoppt vorsorglich die entscheidende Studienphase. Ein Teilnehmer der UK-Studie habe Nebenwirkungen verspürt
![AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
AstraZeneca: Patient erkrankt – Impfstoff-Studie gestoppt!
Rückschlag beim Corona-Impfstoff: Die britische Pharmaschmiede AstraZeneca (WKN: 886455) stoppt vorsorglich die entscheidende Studienphase. Ein Teilnehmer der UK-Studie habe Nebenwirkungen verspürt
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2022-23 season. This
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
GSK plc today announced the first recipient of the Target the Future Think Tank Challenge £70,000 (equivalent to approximately $100,000) grant to the HealthTree Foundation, a non-profit
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of
GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunisation for the prevention of
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
According to a new study conducted by GSK, people age 50 or older in the US who have had COVID-19 may be at greater risk of developing shingles – a painful rash – compared to those who haven’t been
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis
Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
Centers for Disease Control and Prevention (CDC)-recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis
![Mylan Aktie: Positive Aussichten!](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)